Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor

Overview of attention for article published in Journal of Cancer Research and Clinical Oncology, May 1999

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

patent: 28 patents

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 28 patents that reference this research output.

Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor

About this Attention Score

Mentioned by

Citations

Readers on

High-affinity anti-VEGF antibody KLHa505

Grant US-11872271-B2

United States of America

Antibody inhibiting binding of VEGF to NRP1

Grant US-11008387-B2

United States of America

High-affinity anti-VEGF antibody

Grant US-11007259-B2

United States of America

Polynucleotides encoding optimized variants of anti-VEGF antibodies

Grant US-10906968-B2

United States of America

Optimized variants of anti-vegf antibodies and methods of use thereof in treatment

Grant US-10899828-B2

United States of America

Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing…

Grant US-10072075-B2

United States of America

Anti-VEGF antibodies

Grant US-9777059-B2

United States of America

Pulmonary administration of immunoglobulin single variable domains and constructs thereof

Grant US-9725522-B2

United States of America

HIGH-AFFINITY ANTI-VEGF ANTIBODY

Application WO-2017119435-A1

World Intellectual Property Organisation (WIPO)

Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin

Grant US-9505822-B2

United States of America

Recombinant antibodies to the vascular endothelial growth factor (VEGF) which are…

Grant US-9505830-B2

United States of America

Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3…

Grant US-9441026-B2

United States of America

Vascular endothelial growth factor 2

Grant US-9403905-B2

United States of America

Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor

Grant US-9371381-B2

United States of America

Anti-VEGF antibodies

Grant US-9353177-B2

United States of America

Pulmonary administration of immunoglobulin single variable domains and constructs thereof

Grant US-9320792-B2

United States of America

Polypeptide constructs including VHH directed against EGFR for intracellular delivery

Grant US-9243065-B2

United States of America

Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3…

Grant US-9234021-B2

United States of America

Anti-VEGF antibodies

Grant US-9018357-B2

United States of America

Anti-VEGF antibodies

Grant US-8975381-B2

United States of America

Polypeptides Targeting Vascular Endothelial Growth Factor Receptor-2 and Alpha V Beta 3…

Application US-20150005235-A1

United States of America

Anti-VEGF antibodies

Grant US-8921537-B2

United States of America

Vascular endothelial growth factor 2

Grant US-8784809-B2

United States of America

Anti-VEGF antibodies

Grant US-8492527-B2

United States of America

Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis

Grant US-8378071-B2

United States of America